Hyperphosphatemia In Chronic Kidney Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 75 Published: April 05, 2022 Report Code: GMDGDHC13203IDB

  • Overview
  • Key Players
  • Contents
  • Tables
  • Figures
  • FAQ
  • Listen
    iSpeech

Hyperphosphatemia, that is, abnormally high serum phosphate levels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease. Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus, and rash. Treatment includes phosphate binders and diuretics.

The Hyperphosphatemia in Chronic Kidney Disease Drugs in Development market research report provides comprehensive information on the therapeutics under development for Hyperphosphatemia in Chronic Kidney Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperphosphatemia In Chronic Kidney Disease and features dormant and discontinued projects.

What are the targets of Hyperphosphatemia in the chronic kidney disease pipeline drugs market?

The targets of Hyperphosphatemia in the chronic kidney disease pipeline drugs market are Phosphate and Sodium/Hydrogen Exchanger 3.

Hyperphosphatemia in chronic kidney disease pipeline drugs market, by targets

Hyperphosphatemia in chronic kidney disease pipeline drugs market, by targets

For more target insights, download a free report sample

What are the mechanisms of action of Hyperphosphatemia in the chronic kidney disease pipeline drugs market?

The mechanisms of action of Hyperphosphatemia in the chronic kidney disease pipeline drugs market are Phosphate Binder and Sodium/Hydrogen Exchanger 3 Inhibitor.

Hyperphosphatemia in chronic kidney disease pipeline drugs market, by mechanisms of action

Hyperphosphatemia in chronic kidney disease pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

What are the routes of administration in Hyperphosphatemia in the chronic kidney disease pipeline drugs market?

The route of administration in Hyperphosphatemia in the chronic kidney disease pipeline drugs market is oral.

What are the molecule types of Hyperphosphatemia in the chronic kidney disease pipeline drugs market?

The molecule types of Hyperphosphatemia in the chronic kidney disease pipeline drugs market are small molecule and polymer.

Hyperphosphatemia in chronic kidney disease pipeline drugs market, by molecule types

Hyperphosphatemia in chronic kidney disease pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Which are the key companies in Hyperphosphatemia in the chronic kidney disease pipeline drugs market?

The key companies in Hyperphosphatemia in the chronic kidney disease pipeline drugs market are Panion & Bf Biotech Inc, Ardelyx Inc, China Nuokang Bio-Pharmaceutical Inc, Citragen Pharmaceuticals Inc, OPKO Health Inc, Shield Therapeutics Plc, Unicycive Therapeutics Inc, Vidasym Inc, and Vifor Pharma Ltd.

Hyperphosphatemia in chronic kidney disease pipeline drugs market, by key companies

Hyperphosphatemia in chronic kidney disease pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report scope

Targets Phosphate and Sodium/Hydrogen Exchanger 3
Mechanisms of Action Phosphate Binder and Sodium/Hydrogen Exchanger 3 Inhibitor
Routes of Administration Oral
Molecule Types Small Molecule and Polymer
Key Companies Panion & Bf Biotech Inc, Ardelyx Inc, China Nuokang Bio-Pharmaceutical Inc, Citragen Pharmaceuticals Inc, OPKO Health Inc, Shield Therapeutics Plc, Unicycive Therapeutics Inc, Vidasym Inc, and Vifor Pharma Ltd

This report provides:

  • A snapshot of the global therapeutic landscape of Hyperphosphatemia in chronic kidney disease.
  • Reviews of pipeline therapeutics for Hyperphosphatemia in chronic kidney disease by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Key players involved in Hyperphosphatemia in chronic kidney disease therapeutics and enlists all their major and minor projects.
  • Assessment of Hyperphosphatemia in chronic kidney disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Hyperphosphatemia in chronic kidney disease.

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Identify and understand important and diverse types of therapeutics under development for Hyperphosphatemia in chronic kidney disease.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding Hyperphosphatemia in chronic kidney disease pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Key Players

Ardelyx Inc

China Nuokang Bio-Pharmaceutical Inc

Citragen Pharmaceuticals Inc

OPKO Health Inc

Panion & Bf Biotech Inc

Shield Therapeutics Plc

Unicycive Therapeutics Inc

Vidasym Inc

Vifor Pharma Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hyperphosphatemia In Chronic Kidney Disease – Overview

Hyperphosphatemia In Chronic Kidney Disease – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Hyperphosphatemia In Chronic Kidney Disease – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hyperphosphatemia In Chronic Kidney Disease – Companies Involved in Therapeutics Development

Hyperphosphatemia In Chronic Kidney Disease – Drug Profiles

Hyperphosphatemia In Chronic Kidney Disease – Dormant Projects

Hyperphosphatemia In Chronic Kidney Disease – Discontinued Products

Hyperphosphatemia In Chronic Kidney Disease – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Hyperphosphatemia In Chronic Kidney Disease – Pipeline by Ardelyx Inc, 2021

Hyperphosphatemia In Chronic Kidney Disease – Pipeline by China Nuokang Bio-Pharmaceutical Inc, 2021

Hyperphosphatemia In Chronic Kidney Disease – Pipeline by Citragen Pharmaceuticals Inc, 2021

Hyperphosphatemia In Chronic Kidney Disease – Pipeline by OPKO Health Inc, 2021

Hyperphosphatemia In Chronic Kidney Disease – Pipeline by Panion & Bf Biotech Inc, 2021

Hyperphosphatemia In Chronic Kidney Disease – Pipeline by Shield Therapeutics Plc, 2021

Hyperphosphatemia In Chronic Kidney Disease – Pipeline by Unicycive Therapeutics Inc, 2021

Hyperphosphatemia In Chronic Kidney Disease – Pipeline by Vidasym Inc, 2021

Hyperphosphatemia In Chronic Kidney Disease – Pipeline by Vifor Pharma Ltd, 2021

Hyperphosphatemia In Chronic Kidney Disease – Dormant Projects, 2021

Hyperphosphatemia In Chronic Kidney Disease – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

Frequently Asked Questions

The targets of Hyperphosphatemia in the chronic kidney disease pipeline drugs market are Phosphate and Sodium/Hydrogen Exchanger 3.

 

 

The mechanisms of action of Hyperphosphatemia in the chronic kidney disease pipeline drugs market are Phosphate Binder and Sodium/Hydrogen Exchanger 3 Inhibitor.

The route of administration in Hyperphosphatemia in the chronic kidney disease pipeline drugs market is oral.

The molecule types in Hyperphosphatemia in the chronic kidney disease pipeline drugs market are small molecule and polymer.

The key companies in Hyperphosphatemia in the chronic kidney disease pipeline drugs market are Panion & Bf Biotech Inc, Ardelyx Inc, China Nuokang Bio-Pharmaceutical Inc, Citragen Pharmaceuticals Inc, OPKO Health Inc, Shield Therapeutics Plc, Unicycive Therapeutics Inc, Vidasym Inc, and Vifor Pharma Ltd.

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.